サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1409867

腫瘍壊死因子（TNF）阻害薬の世界市場レポート 2024年

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
腫瘍壊死因子（TNF）阻害薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

腫瘍壊死因子（TNF）阻害薬市場規模は近年わずかながら成長しています。2023年の420億1,000万米ドルから2024年には427億5,000万米ドルへと、CAGR1.8%で拡大する見込みです。過去の期間に見られた成長は、TNF阻害剤の臨床的有効性の実証、FDA（米国食品医薬品局）の承認、これらの薬剤で治療可能な疾患の有病率の上昇、その有効性を検証する広範な臨床試験や調査、医師によるこれらの薬剤の採用や支持、患者の間でこれらの治療に対する需要が高まり、満足度が高まったことなど、いくつかの要因によるものです。

腫瘍壊死因子（TNF）阻害薬の市場規模は、今後数年間で安定した成長が見込まれます。2028年の年間平均成長率（CAGR）は2.3％で、469億米ドルに成長します。予測期間の成長は、新興市場の拡大、規制の変更とその後の承認、個別化医療アプローチの採用、ヘルスケアに対する認識とアクセシビリティの向上、生物学的療法の進歩など、さまざまな要因に起因すると予想されます。予測期間中に予測される主な動向には、患者中心のソリューションの台頭、治療アプローチにおける実臨床のエビデンスとデータの活用、薬剤の安全性の確保と潜在的な副作用の管理への関心の高まり、先進的ドラッグデリバリーシステムの進歩、TNF阻害薬の臨床応用の拡大などが含まれます。

自己免疫疾患の有病率の上昇は、腫瘍壊死因子（TNF）阻害薬市場の成長を牽引する見通しです。自己免疫疾患は、免疫系が誤って健康な人体組織を攻撃することを特徴とし、しばしば炎症、痛み、腫れを引き起こします。腫瘍壊死因子（TNF）阻害薬は、炎症をブロックし、関連症状を緩和し、免疫系を安定させることにより、これらの影響を緩和する上で重要な役割を果たしています。2022年6月現在、自己免疫学会の報告によると、米国では470万人の男性が自己免疫疾患に罹患しており、自己免疫疾患患者全体の20％を占めています。さらに、2022年には米国で合計3,100万人が80～150種の自己免疫疾患に罹患していると報告されており、今後さらに増加することが予想されます。その結果、自己免疫疾患の有病率の上昇が腫瘍壊死因子（TNF）阻害薬市場の成長の原動力となっています。

腫瘍壊死因子（TNF）阻害薬市場の成長は、ヘルスケア支出の増加によって促進されると予測されます。ヘルスケア支出とは、特定の期間内にヘルスケア関連のサービス、製品、活動に費やされる総額を指します。ヘルスケア支出の増加は、TNF阻害剤のような生物学的製剤を含む、高度で高価な治療法へのアクセスの改善に関連することが多いです。その結果、ヘルスケア支出の増加傾向は、腫瘍壊死因子（TNF）阻害薬市場の成長を促進するものと思われます。

2023年の腫瘍壊死因子（TNF）阻害薬市場で最大の地域は北米でした。アジア太平洋は、予測期間中、腫瘍壊死因子（TNF）阻害薬市場レポートにおいて最も急成長している地域になると予測されています。腫瘍壊死因子（TNF）阻害薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 腫瘍壊死因子（TNF）阻害薬市場の特徴

第3章 腫瘍壊死因子（TNF）阻害薬市場の動向と戦略

第4章 腫瘍壊死因子（TNF）阻害薬市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の腫瘍壊死因子（TNF）阻害薬市場規模と成長

  • 世界の腫瘍壊死因子（TNF）阻害薬市場促進要因と制約要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の腫瘍壊死因子（TNF）阻害薬の市場規模実績と成長、2018年から2023年
  • 世界の腫瘍壊死因子（TNF）阻害薬市場規模と成長予測、2023年～2028年、2033年

第6章 腫瘍壊死因子（TNF）阻害薬市場セグメンテーション

  • 世界の腫瘍壊死因子（TNF）阻害薬市場、製品タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ヒュミラ
  • エンブレル
  • レミケード
  • シンポニ/シンポニ・アリア
  • シムジア
  • バイオシミラー
  • 世界の腫瘍壊死因子（TNF）阻害薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 皮下注射
  • 静脈注射
  • 世界の腫瘍壊死因子（TNF）阻害薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の腫瘍壊死因子（TNF）阻害薬市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 関節リウマチ
  • 乾癬
  • 乾癬性関節炎
  • クローン病
  • 潰瘍性大腸炎
  • 強直性脊椎炎
  • 若年性特発性関節炎
  • 化膿性汗腺炎
  • その他の用途

第7章 腫瘍壊死因子（TNF）阻害薬市場の地域および国分析

  • 世界の腫瘍壊死因子（TNF）阻害薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の腫瘍壊死因子（TNF）阻害薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の腫瘍壊死因子（TNF）阻害薬市場

第9章 中国の腫瘍壊死因子（TNF）阻害薬市場

第10章 インドの腫瘍壊死因子（TNF）阻害薬市場

第11章 日本の腫瘍壊死因子（TNF）阻害薬市場

第12章 オーストラリアの腫瘍壊死因子（TNF）阻害薬市場

第13章 インドネシアの腫瘍壊死因子（TNF）阻害薬市場

第14章 韓国の腫瘍壊死因子（TNF）阻害薬市場

第15章 西欧の腫瘍壊死因子（TNF）阻害薬市場

第16章 英国の腫瘍壊死因子（TNF）阻害薬市場

第17章 ドイツの腫瘍壊死因子（TNF）阻害薬市場

第18章 フランスの腫瘍壊死因子（TNF）阻害薬市場

第19章 イタリアの腫瘍壊死因子（TNF）阻害薬市場

第20章 スペインの腫瘍壊死因子（TNF）阻害薬市場

第21章 東欧の腫瘍壊死因子（TNF）阻害薬市場

第22章 ロシアの腫瘍壊死因子（TNF）阻害薬市場

第23章 北米の腫瘍壊死因子（TNF）阻害薬市場

第24章 米国の腫瘍壊死因子（TNF）阻害薬市場

第25章 カナダの腫瘍壊死因子（TNF）阻害薬市場

第26章 南米の腫瘍壊死因子（TNF）阻害薬市場

第27章 ブラジルの腫瘍壊死因子（TNF）阻害薬市場

第28章 中東の腫瘍壊死因子（TNF）阻害薬市場

第29章 アフリカの腫瘍壊死因子（TNF）阻害薬市場

第30章 腫瘍壊死因子（TNF）阻害薬市場の競合情勢と企業プロファイル

  • 腫瘍壊死因子（TNF）阻害薬市場の競合情勢
  • 腫瘍壊死因子（TNF）阻害薬市場の企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson &Johnson Services Inc.
    • UCB SA
    • Novartis International AG

第31章 世界の腫瘍壊死因子（TNF）阻害薬市場の競合ベンチマーキング

第32章 世界の腫瘍壊死因子（TNF）阻害薬市場競争力ダッシュボード

第33章 腫瘍壊死因子（TNF）阻害薬市場における主要な合併と買収

第34章 腫瘍壊死因子（TNF）阻害薬市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r11405

“Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tumor necrosis factor inhibitor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tumor necrosis factor inhibitor drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The tumor necrosis factor inhibitor drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product Type: Humira; Enbrel; Remicade; Simponi/Simponi Aria; Cimzia; Biosimilars
  • 2) By Route Of Administration: Subcutaneous Injection; Intravenous Injection
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 4) By Application: Rheumatoid Arthritis; Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Ankylosing Spondylitis; Juvenile Idiopathic Arthritis; Hidradenitis Suppurativa; Other Applications
  • Companies Mentioned: AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services Inc.; UCB S.A.; Novartis International AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Tumor necrosis factor (TNF) inhibitor drugs are medications designed to alleviate inflammation. These drugs work by suppressing the inflammatory response triggered by TNF cytokines, thereby treating various inflammatory and autoimmune conditions.

Key types of TNF inhibitor drugs available in the market include Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars. Humira, for instance, is a TNF blocker that diminishes the effects of substances in the body responsible for inflammation. These medications are administered via subcutaneous or intravenous injection routes and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are prescribed for conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, among others, to mitigate their symptoms and manage the underlying inflammation.

The tumor necrosis factor (TNF) inhibitor drugs market research report is one of a series of new reports from The Business Research Company that provides tumor necrosis factor (TNF) inhibitor drugs market statistics, including global market size, regional shares, competitors with a tumor necrosis factor (TNF) inhibitor drugs market share, detailed tumor necrosis factor (TNF) inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tumor necrosis factor (TNF) inhibitor drugs industry. This tumor necrosis factor (TNF) inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor necrosis factor inhibitor drugs market size has grown marginally in recent years. It will grow from $42.01 billion in 2023 to $42.75 billion in 2024 at a compound annual growth rate (CAGR) of 1.8%. The growth observed in the historical period can be attributed to several contributing factors, including the demonstrated clinical efficacy of TNF inhibitor drugs, approvals from the FDA (Food and Drug Administration), a rise in the prevalence of diseases treatable by these medications, extensive clinical trials and research validating their effectiveness, the adoption and endorsement of these drugs by physicians, as well as increasing demand for these treatments among patients, leading to greater satisfaction.

The tumor necrosis factor inhibitor drugs market size is expected to see steady growth in the next few years. It will grow to $46.9 billion in 2028 at a compound annual growth rate (CAGR) of 2.3%. Anticipated growth in the forecast period is expected to stem from various factors, including the expansion of emerging markets, regulatory changes and subsequent approvals, the adoption of personalized medicine approaches, increased healthcare awareness and accessibility, and advancements in biological therapies. Key trends projected in the forecast period encompass the rise of patient-centric solutions, the utilization of real-world evidence and data in treatment approaches, a heightened focus on ensuring drug safety and managing potential side effects, advancements in advanced drug delivery systems, and the broadening of clinical applications for TNF inhibitor drugs.

The rising prevalence of autoimmune illnesses is poised to drive the growth of the tumor necrosis factor inhibitor drugs market. Autoimmune disorders, characterized by the immune system mistakenly attacking healthy human tissue, often result in inflammation, pain, and swelling. Tumor necrosis factor inhibitor drugs play a crucial role in mitigating these effects by blocking inflammation, providing relief from associated symptoms, and stabilizing the immune system. As of June 2022, the Autoimmune Association reported that 4.7 million men in the US were affected by autoimmune diseases, constituting 20% of all autoimmune disease patients. Additionally, a total of 31 million individuals in the US were reported to be suffering from 80-150 unique autoimmune diseases in 2022, with expectations of further increases in the future. Consequently, the escalating prevalence of autoimmune disorders serves as a driving force for the growth of the tumor necrosis factor inhibitor drugs market.

The growth of the tumor necrosis factor inhibitor drug market is anticipated to be fueled by increasing healthcare expenditures. Healthcare expenditures encompass the total amount spent on healthcare-related services, products, and activities within a specified period. Higher healthcare spending is often associated with improved access to advanced and expensive treatments, including biologic drugs such as TNF inhibitors. For instance, as of May 2023, the Office for National Statistics in the UK reported a 9.4% increase in nominal terms and a 9.7% increase in real terms in healthcare spending. The UK's total healthcare expenditure in 2021 amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion). Notably, spending on preventive care more than doubled from the previous year, reaching $45.93 billion (£35.1 billion) in 2021. Consequently, the upward trend in healthcare expenditure is poised to drive the growth of the tumor necrosis factor inhibitor drug market.

Product innovations stand out as a key trend gaining momentum in the tumor necrosis factor inhibitor drugs market, with major companies directing their efforts towards developing cutting-edge products to enhance their market positions. An illustrative example is Pfizer Inc, a prominent US-based company in the tumor necrosis factor inhibitor drugs sector. In December 2021, Pfizer launched XELJANZ, a novel treatment designed for ankylosing spondylitis (AS) patients who have not responded well to one or more TNF blockers. XELJANZ provides a unique treatment option for AS, offering an alternative to injections or infusions for this chronic immuno-inflammatory disease. The drug operates by blocking the action of Janus kinase enzymes involved in inflammation.

Major players in the tumor necrosis factor inhibitor drug market are strategically embracing a partnership approach to create a new oral medicine for irritable bowel disease (IBD). Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits. In July 2022, SGS S.A., a Switzerland-based inspection, verification, testing, and certification service, announced a collaboration with CPI, Pharmidex, and Intract Pharma. The partnership aims to repackage the biologic medication infliximab, a tumor necrosis factor (TNF) inhibitor drug used for various inflammatory conditions, including IBD, into an oral capsule. This innovative oral delivery method for infliximab seeks to provide IBD patients with a more focused, convenient, and safer treatment option by withstanding the harsh conditions of the stomach. Intract Pharma Limited, Pharmidex Pharmaceutical Services Ltd., and CPI are all UK-based entities contributing their expertise to this collaborative effort.

In April 2022, Samsung Biologics, a prominent South Korea-based biotechnology company, successfully acquired Samsung Bioepis Co. Ltd. for a significant sum of $2.3 billion. This strategic acquisition is poised to enhance Samsung Biologics' capabilities in biosimilar development and position the company for improved performance in the realm of novel drug development. The acquisition is expected to provide Samsung Bioepis with greater autonomy and agility in its business operations. Samsung Bioepis Co. Ltd., also based in South Korea, is a leading biopharmaceutical company specializing in the production of tumor necrosis factor inhibitor drugs. The acquisition marks a significant move for Samsung Biologics to bolster its position in the biopharmaceutical industry and further its contributions to the development of vital medications in the tumor necrosis factor inhibitor drugs market.

Major companies operating in the tumor necrosis factor inhibitor drugs market report are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Pfizer Inc., Samsung Bioepis Co. Ltd., Sanofi SA, Merck & Co. Inc., Boehringer Ingelheim Pharmaceuticals, Lupin Ltd., Ablynx NV, Momenta Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Cadila Healthcare Ltd., Apogenix AG, Aryogen Biopharma, Bionovis, Casi Pharmaceuticals, Celltrion Inc., Bristol-Myers Squibb, Delenex Therapeutics, Dexa Medica, Epirus Biopharmaceuticals, Glaxosmithkline plc, Hanall Biopharma, Intas Pharmaceuticals, Leo Pharma AS, LG Chem Ltd., Biogen Inc. .

North America was the largest region in the tumor necrosis factor inhibitor drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the tumor necrosis factor (TNF) inhibitors drugs market report during the forecast period. The regions covered in the tumor necrosis factor inhibitor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the tumor necrosis factor inhibitor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tumor necrosis factor (TNF) inhibitors drugs market consists of sales of enbrel, ereizi, inflectra, and renflexis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Tumor Necrosis Factor Inhibitor Drugs Market Characteristics

3. Tumor Necrosis Factor Inhibitor Drugs Market Trends And Strategies

4. Tumor Necrosis Factor Inhibitor Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Tumor Necrosis Factor Inhibitor Drugs Market Size and Growth

  • 5.1. Global Tumor Necrosis Factor Inhibitor Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Tumor Necrosis Factor Inhibitor Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Tumor Necrosis Factor Inhibitor Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Tumor Necrosis Factor Inhibitor Drugs Market Segmentation

  • 6.1. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars
  • 6.2. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Subcutaneous Injection
  • Intravenous Injection
  • 6.3. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Rheumatoid Arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Crohn's Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Other Applications

7. Tumor Necrosis Factor Inhibitor Drugs Market Regional And Country Analysis

  • 7.1. Global Tumor Necrosis Factor Inhibitor Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Tumor Necrosis Factor Inhibitor Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market

  • 8.1. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Tumor Necrosis Factor Inhibitor Drugs Market

  • 9.1. China Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 9.2. China Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Tumor Necrosis Factor Inhibitor Drugs Market

  • 10.1. India Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Tumor Necrosis Factor Inhibitor Drugs Market

  • 11.1. Japan Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 11.2. Japan Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Tumor Necrosis Factor Inhibitor Drugs Market

  • 12.1. Australia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market

  • 13.1. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Tumor Necrosis Factor Inhibitor Drugs Market

  • 14.1. South Korea Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 14.2. South Korea Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market

  • 15.1. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 15.2. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Tumor Necrosis Factor Inhibitor Drugs Market

  • 16.1. UK Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Tumor Necrosis Factor Inhibitor Drugs Market

  • 17.1. Germany Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Tumor Necrosis Factor Inhibitor Drugs Market

  • 18.1. France Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Tumor Necrosis Factor Inhibitor Drugs Market

  • 19.1. Italy Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Tumor Necrosis Factor Inhibitor Drugs Market

  • 20.1. Spain Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market

  • 21.1. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 21.2. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Tumor Necrosis Factor Inhibitor Drugs Market

  • 22.1. Russia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Tumor Necrosis Factor Inhibitor Drugs Market

  • 23.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 23.2. North America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Tumor Necrosis Factor Inhibitor Drugs Market

  • 24.1. USA Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 24.2. USA Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Tumor Necrosis Factor Inhibitor Drugs Market

  • 25.1. Canada Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 25.2. Canada Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Tumor Necrosis Factor Inhibitor Drugs Market

  • 26.1. South America Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 26.2. South America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Tumor Necrosis Factor Inhibitor Drugs Market

  • 27.1. Brazil Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Tumor Necrosis Factor Inhibitor Drugs Market

  • 28.1. Middle East Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 28.2. Middle East Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Tumor Necrosis Factor Inhibitor Drugs Market

  • 29.1. Africa Tumor Necrosis Factor Inhibitor Drugs Market Overview
  • 29.2. Africa Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Tumor Necrosis Factor Inhibitor Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Tumor Necrosis Factor Inhibitor Drugs Market Competitive Landscape
  • 30.2. Tumor Necrosis Factor Inhibitor Drugs Market Company Profiles
    • 30.2.1. AbbVie Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Amgen Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Johnson & Johnson Services Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. UCB S.A.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis International AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Tumor Necrosis Factor Inhibitor Drugs Market Competitive Benchmarking

32. Global Tumor Necrosis Factor Inhibitor Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Tumor Necrosis Factor Inhibitor Drugs Market

34. Tumor Necrosis Factor Inhibitor Drugs Market Future Outlook and Potential Analysis

  • 34.1 Tumor Necrosis Factor Inhibitor Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Tumor Necrosis Factor Inhibitor Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Tumor Necrosis Factor Inhibitor Drugs Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer